

Treatment algorithm for Ulcerative Colitis (June 2016)

Note 1: Less expensive drug

As assessment of the less expensive drug should take into account:

- Drug administration costs
- Required dose
- Product price per dose

The assessment of the less expensive drug may need to be varied for individual patients because of differences in the method of administration and treatment schedules

Note 2: disease reassessment

At 12 months after the start of treatment, people should have their disease reassessed to determine whether ongoing treatment is still clinically appropriate. Treatment should only be continued if there is clear evidence of ongoing active disease. This should be determined by

- Clinical symptoms and
- biological markers and
- investigation, including endoscopy if necessary

Note 3: Infliximab prescribing

Infliximab should be prescribed by brand.

- Infliximab - remicade
- Infliximab (biosimilar) - remsima
- Infliximab (biosimilar) - inflectra

